Compare CMT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | IVVD |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | 1239 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.1M | 212.6M |
| IPO Year | 1996 | 2021 |
| Metric | CMT | IVVD |
|---|---|---|
| Price | $21.61 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 32.6K | ★ 4.2M |
| Earning Date | 11-03-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $284,290,000.00 | $53,426,000.00 |
| Revenue This Year | $4.20 | $12.40 |
| Revenue Next Year | $6.33 | $44.85 |
| P/E Ratio | $84.33 | ★ N/A |
| Revenue Growth | 5.49 | ★ 110.47 |
| 52 Week Low | $17.36 | $0.53 |
| 52 Week High | $28.69 | $3.07 |
| Indicator | CMT | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 41.24 |
| Support Level | $22.75 | $0.60 |
| Resistance Level | $24.67 | $1.02 |
| Average True Range (ATR) | 0.81 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 52.78 | 43.67 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.